These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 31004262)
1. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours. Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262 [TBL] [Abstract][Full Text] [Related]
2. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684 [TBL] [Abstract][Full Text] [Related]
3. IDH1 Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042 [TBL] [Abstract][Full Text] [Related]
4. [The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples]. Shi J; Zhao Y; Yuan Y; Wang C; Xie Z; Gao X; Xiao L; Ye J Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):360-3. PubMed ID: 26927556 [TBL] [Abstract][Full Text] [Related]
5. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787 [TBL] [Abstract][Full Text] [Related]
6. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887 [TBL] [Abstract][Full Text] [Related]
7. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma. Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525 [TBL] [Abstract][Full Text] [Related]
9. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas. Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759 [TBL] [Abstract][Full Text] [Related]
10. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953 [TBL] [Abstract][Full Text] [Related]
11. Integrated molecular characterization of IDH-mutant glioblastomas. Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163 [TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047 [TBL] [Abstract][Full Text] [Related]
13. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma. Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032 [TBL] [Abstract][Full Text] [Related]
14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
15. In vivo Metabolic Profiles as Determined by Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683 [TBL] [Abstract][Full Text] [Related]
16. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases. Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787 [TBL] [Abstract][Full Text] [Related]
17. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723 [TBL] [Abstract][Full Text] [Related]
18. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414 [TBL] [Abstract][Full Text] [Related]
19. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
20. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]